⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INO News
Inovio Pharmaceuticals, Inc.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INO
accessnewswire.com
INO
Shareholder Rights Law Firm Robbins LLP Urges INO Stockholders to Contact the Firm for Information About Leading the Inovio Pharmaceuticals, Inc. Class Action
accessnewswire.com
INO
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm, Encourages Inovio Pharmaceuticals, Inc. (INO) Shareholders to Inquire About Securities Fraud Class Action
businesswire.com
INO
Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm, Encourages Inovio Pharmaceuticals, Inc. (INO) Shareholders to Inquire About Securities Fraud Class Action
businesswire.com
INO
Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc.and Certain Officers – INO
globenewswire.com
INO
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
globenewswire.com
INO
Artis BioSolutions Appoints Dr. Kate Broderick, Ph.D., as Chief Scientific Innovation Officer to Advance Synthetic DNA Strategy
businesswire.com
MRVI
INO
Artis BioSolutions Appoints Dr. Kate Broderick, Ph.D., as Chief Scientific Innovation Officer to Advance Synthetic DNA Strategy
businesswire.com
MRVI
INO
INO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Inovio Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
accessnewswire.com
INO
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit
prnewswire.com
INO